MacroH2A1 Immunoexpression in Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Sep 25

PMID 32974186

Citations 22

Authors

Giuseppe Broggi

Veronica Filetti

Antonio Ieni

Venerando Rapisarda

Caterina Ledda

Ermanno Vitale

Silvia Varricchio

Daniela Russo

Claudia Lombardo

Giovanni Tuccari

Rosario Caltabiano

Carla Loreto

Affiliations

Soon will be listed here.

Abstract

MacroH2A1 has two splice isoforms, macroH2A1.1 and macroH2A1.2, that have been studied in several form of cancer. In the literature there are not many scientific papers dealing with the role of macroH2A1 in breast cancer. Breast cancer is the most frequent form of malignancy in females. It tend to metastasize to the bone in ~70% of patients. Despite treatment, new bone metastases will still occur in 30-50% of cases with advanced disease. Overall 5-year survival after the diagnosis of bone metastasis is ~20%. Osteoclasts and osteoblasts of the bone microenvironment are engaged by soluble factors released by neoplastic cells, resulting in bone matrix breakdown. This malfunction enhances the proliferation of the cancer cells, creating a vicious cycle. We investigated immunohistochemical expression of macroH2A1 in primitive breast cancer, focusing on the comparison of metastatic and non-metastatic cases. Furthermore, the immunohistochemical expression of macroH2A1 has been evaluated both in all cases of nodal metastases and in distant metastases. Our data demonstrated that macroH2A1 expression was higher expressed in metastatic breast cancer (77%) vs. non-metastatic breast cancer (32%). Also in analyzed metastases cases, a high macroH2A1 expression was detected: 85 and 80% in nodal and distant metastases cases, respectively. These results supported the fact that macroH2A1 is more highly expressed in breast cancer with worst prognosis.

Citing Articles

Roles of Histone H2A Variants in Cancer Development, Prognosis, and Treatment.

Lai P, Chan K Int J Mol Sci. 2024; 25(6).

PMID: 38542118 PMC: 10969971. DOI: 10.3390/ijms25063144.

MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes.

Giallongo C, Dulcamare I, Giallongo S, Duminuco A, Pieragostino D, Cufaro M Cell Death Dis. 2023; 14(10):686.

PMID: 37852977 PMC: 10584900. DOI: 10.1038/s41419-023-06197-x.

Brain Metastases from Breast Cancer Histologically Exhibit Solid Growth Pattern with at Least Focal Comedonecrosis: A Histopathologic Study on a Monocentric Series of 30 Cases.

Farina J, Angelico G, Vecchio G, Salvatorelli L, Magro G, Puzzo L Diagnostics (Basel). 2023; 13(19).

PMID: 37835885 PMC: 10572254. DOI: 10.3390/diagnostics13193141.

Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4.

Aldahlawi A, Basingab F, Alrahimi J, Zaher K, Pushparaj P, Hassan M Biomed Rep. 2023; 19(2):56.

PMID: 37560313 PMC: 10407466. DOI: 10.3892/br.2023.1638.

DNA oxidative damage in oral cancer: 8-hydroxy-2´-deoxyguanosine immunoexpression assessment.

Prieto-Correa J, Bologna-Molina R, Gonzalez-Gonzalez R, Molina-Frechero N, Soto-Avila J, Isiordia-Espinoza M Med Oral Patol Oral Cir Bucal. 2023; 28(6):e530-e538.

PMID: 37471300 PMC: 10635627. DOI: 10.4317/medoral.25924.

References

Kim J, Shin Y, Lee S, Kim M, Punj V, Lu J . Regulation of Breast Cancer-Induced Osteoclastogenesis by MacroH2A1.2 Involving EZH2-Mediated H3K27me3. Cell Rep. 2018; 24(1):224-237. PMC: 6061927. DOI: 10.1016/j.celrep.2018.06.020. View

Costanzi C, Pehrson J . Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature. 1998; 393(6685):599-601. DOI: 10.1038/31275. View

Shemanko C, Cong Y, Forsyth A . What Is Breast in the Bone?. Int J Mol Sci. 2016; 17(10). PMC: 5085788. DOI: 10.3390/ijms17101764. View

Villarreal-Garza C, Aguila C, Magallanes-Hoyos M, Mohar A, Bargallo E, Meneses A . Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013; 18(12):1298-306. PMC: 3868424. DOI: 10.1634/theoncologist.2013-0321. View

Wutz A, Rasmussen T, Jaenisch R . Chromosomal silencing and localization are mediated by different domains of Xist RNA. Nat Genet. 2002; 30(2):167-74. DOI: 10.1038/ng820. View

Pehrson J, Fried V . MacroH2A, a core histone containing a large nonhistone region. Science. 1992; 257(5075):1398-400. DOI: 10.1126/science.1529340. View

Kim J, Shin Y, Lee S, Kim M, Punj V, Shin H . MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1α and H1.2. Oncogene. 2018; 37(43):5749-5765. PMC: 6309402. DOI: 10.1038/s41388-018-0356-3. View

Changolkar L, Pehrson J . macroH2A1 histone variants are depleted on active genes but concentrated on the inactive X chromosome. Mol Cell Biol. 2006; 26(12):4410-20. PMC: 1489112. DOI: 10.1128/MCB.02258-05. View

Vieira-Silva T, Monteiro-Reis S, Barros-Silva D, Ramalho-Carvalho J, Graca I, Carneiro I . Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype. Cancer Cell Int. 2019; 19:112. PMC: 6489299. DOI: 10.1186/s12935-019-0835-9. View

10.

Ouararhni K, Hadj-Slimane R, Ait-Si-Ali S, Robin P, Mietton F, Harel-Bellan A . The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity. Genes Dev. 2006; 20(23):3324-36. PMC: 1686608. DOI: 10.1101/gad.396106. View

11.

Changolkar L, Costanzi C, Leu N, Chen D, McLaughlin K, Pehrson J . Developmental changes in histone macroH2A1-mediated gene regulation. Mol Cell Biol. 2007; 27(7):2758-64. PMC: 1899912. DOI: 10.1128/MCB.02334-06. View

12.

Tsukasaki M, Hamada K, Okamoto K, Nagashima K, Terashima A, Komatsu N . LOX Fails to Substitute for RANKL in Osteoclastogenesis. J Bone Miner Res. 2016; 32(3):434-439. DOI: 10.1002/jbmr.2990. View

13.

Sporn J, Kustatscher G, Hothorn T, Collado M, Serrano M, Muley T . Histone macroH2A isoforms predict the risk of lung cancer recurrence. Oncogene. 2009; 28(38):3423-8. DOI: 10.1038/onc.2009.26. View

14.

Loreto C, Lombardo C, Caltabiano R, Filetti V, Vitale E, Seminara D . Immunohistochemical expression and localization of MMP-9, MMP-13, E-Cadherin and Ki-67 in road pavers' skin chronically exposed to bitumen products. Histol Histopathol. 2019; 34(10):1141-1150. DOI: 10.14670/HH-18-116. View

15.

Caltabiano R, Puzzo L, Barresi V, Ieni A, Loreto C, Musumeci G . ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis. Pathol Res Pract. 2016; 212(11):980-987. DOI: 10.1016/j.prp.2016.08.003. View

16.

Musumeci G, Trovato F, Loreto C, Leonardi R, Szychlinska M, Castorina S . Lubricin expression in human osteoarthritic knee meniscus and synovial fluid: a morphological, immunohistochemical and biochemical study. Acta Histochem. 2014; 116(5):965-72. DOI: 10.1016/j.acthis.2014.03.011. View

17.

Hernandez-Munoz I, Lund A, van der Stoop P, Boutsma E, Muijrers I, Verhoeven E . Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci U S A. 2005; 102(21):7635-40. PMC: 1140410. DOI: 10.1073/pnas.0408918102. View

18.

Gamble M, Frizzell K, Yang C, Krishnakumar R, Kraus W . The histone variant macroH2A1 marks repressed autosomal chromatin, but protects a subset of its target genes from silencing. Genes Dev. 2009; 24(1):21-32. PMC: 2802188. DOI: 10.1101/gad.1876110. View

19.

Sporn J, Jung B . Differential regulation and predictive potential of MacroH2A1 isoforms in colon cancer. Am J Pathol. 2012; 180(6):2516-26. PMC: 3717782. DOI: 10.1016/j.ajpath.2012.02.027. View

20.

Kapoor A, Goldberg M, Cumberland L, Ratnakumar K, Segura M, Emanuel P . The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature. 2010; 468(7327):1105-9. PMC: 3057940. DOI: 10.1038/nature09590. View